ellipticine has been researched along with Brain Neoplasms in 4 studies
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cytotoxicity of ellipticine to neuroblastomas was increased by pre-treating these cells with VPA or TSA." | 7.77 | Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. ( Dvorakova, M; Eckschlager, T; Frei, E; Göttlicherova, M; Hrabeta, J; Hrebackova, J; Kizek, R; Kopejtkova, B; Moserova, M; Poljakova, J; Stiborova, M, 2011) |
| "The cytotoxicity of ellipticine to neuroblastomas was increased by pre-treating these cells with VPA or TSA." | 3.77 | Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. ( Dvorakova, M; Eckschlager, T; Frei, E; Göttlicherova, M; Hrabeta, J; Hrebackova, J; Kizek, R; Kopejtkova, B; Moserova, M; Poljakova, J; Stiborova, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acton, EM | 1 |
| Narayanan, VL | 1 |
| Risbood, PA | 1 |
| Shoemaker, RH | 1 |
| Vistica, DT | 1 |
| Boyd, MR | 1 |
| Jurayj, J | 1 |
| Haugwitz, RD | 1 |
| Varma, RK | 1 |
| Paull, KD | 1 |
| Barrett, JF | 1 |
| Cushman, M | 1 |
| Banerjee, S | 1 |
| Pabbathi, A | 1 |
| Sekhar, MC | 1 |
| Samanta, A | 1 |
| Poljakova, J | 1 |
| Hrebackova, J | 1 |
| Dvorakova, M | 1 |
| Moserova, M | 1 |
| Eckschlager, T | 1 |
| Hrabeta, J | 1 |
| Göttlicherova, M | 1 |
| Kopejtkova, B | 1 |
| Frei, E | 1 |
| Kizek, R | 1 |
| Stiborova, M | 1 |
4 other studies available for ellipticine and Brain Neoplasms
| Article | Year |
|---|---|
Anticancer specificity of some ellipticinium salts against human brain tumors in vitro.
Topics: Brain Neoplasms; Drug Evaluation, Preclinical; Ellipticines; Humans; Structure-Activity Relationship | 1994 |
Design and synthesis of ellipticinium salts and 1,2-dihydroellipticines with high selectivities against human CNS cancers in vitro.
Topics: Brain Neoplasms; Drug Design; Drug Evaluation, Preclinical; Ellipticines; Humans; Structure-Activity | 1994 |
Dual fluorescence of ellipticine: excited state proton transfer from solvent versus solvent mediated intramolecular proton transfer.
Topics: Antineoplastic Agents; Brain Neoplasms; Ellipticines; Fluorescence; Humans; Hydrogen Bonding; Hydrop | 2011 |
Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; DNA Damage; Dose-Response | 2011 |